医学
重症肌无力
耐受性
乙酰胆碱受体
耐火材料(行星科学)
生活质量(医疗保健)
免疫疗法
抗体
药理学
内科学
受体
免疫学
不利影响
免疫系统
物理
护理部
天体生物学
作者
Shigeaki Suzuki,Akiyuki Uzawa,Hiroyuki Murai
标识
DOI:10.1080/1744666x.2022.2136167
摘要
The management of myasthenia gravis (MG) has been improved due to immunotherapy advances, but 20% of individuals with MG are refractory to the conventional therapy, and the need for novel biological drugs remains.The Japanese clinical guidelines for MG published in May 2022 include the concept that treatment is often lifelong and should aim to maintain a sufficient quality of life and mental health. We provide an overview of the therapeutic strategy for generalized MG in Japan, in comparison with the international consensus. We summarize the clinical efficacy, safety, and tolerability of efgartigimod, the first approved anti-neonatal Fc receptor inhibitor for MG. A phase III study showed that efgartigimod was well-tolerated and efficacious in patients with generalized MG.Efgartigimod is a promising biological drug for patients with moderate to severe generalized MG with or without anti-acetylcholine receptor antibodies in Japan.
科研通智能强力驱动
Strongly Powered by AbleSci AI